962 A novel alpha-active IL-2-Fc has expanded therapeutic index and robust monotherapy efficacy in mouse cancer models and strong synergy with PD-1 blockadeAdam Stockmann, Ann Cheung, S.R. Vincent et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0
DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activityAdam Stockmann, Ann Cheung, Jingya Ma et al.|Cell Reports Medicine|2025Cited by 0